‡ In these countries please contact our distributor

E - Edge

The products used in the T.I.M.E. clinical decision support tool may vary in different markets.  Not all products referred to may be approved for use or available in all markets.  Please consult your local Smith & Nephew representative for further details on products available in your market. 


Aim to facilitate advancement of the wound edge

Once tissue viability, infection and moisture have been addressed, the wound epithelial edge advancement should indicate healing progression and treatment success1-2.


Assess the wound to identify the right treatment or intervention


Coming soon: Our T.I.M.E. clinical decision support tool. Register here for notifications >


Wound edge abnormal or not advancing: aim to promote epithelialization and healthy periwound skin, with growth factors, wound matrix dressings, collagen matrix dressings or Negative Pressure Wound Therapy (NPWT).

BIOSTEP Collagen Matrix Dressing
REGRANEX (Becaplermin) Gel 0.01%*
OASIS Wound Matrix
PICO 7 Single Use Negative Pressure Wound Therapy System (sNPWT)
RENASYS Traditional Negative Pressure Wound Therapy
SECURA Skin Care - prepare, protect, moisturise and cleanse


  Next step > Evaluate the effectiveness of treatment and progression towards your wound management goal.


For additional product information or ordering instructions, arrange a call from a Smith & Nephew representative.


Helping you get CLOSER TO ZERO human and economic cost of wounds. 

A healthcare professional must always rely on his or her own professional clinical judgment when deciding whether to use a particular product when treating a particular patient. Smith & Nephew does not dispense medical advice and recommends that healthcare professionals be trained in the use of any particular product before using it on patients.

For detailed product information, including indications for use, contraindications, effects, precautions, warnings, and important safety information, please consult the Instructions for Use (IFU) prior to use.


*REGRANEX gel is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply when used as an adjunct to, and not a substitute for, good ulcer care practices. The efficacy of REGRANEX gel has not been established for the treatment of pressure ulcers and venous stasis ulcers. The effects of REGRANEX gel on exposed joints, tendons, ligaments, and bone have not been established in humans. REGRANEX gel is a non-sterile, low bioburden preserved product. Therefore, it should not be used in wounds that close by primary intention. Malignancies distant from the site of application have been reported in both a clinical study and in postmarketing use. The benefits and risks of REGRANEX gel treatment should be carefully evaluated before prescribing in patients with known malignancy. See complete prescribing information for more details.



1) Leaper DJ, Schultz G, Carville K, Fletcher J, Swanson T, Drake R. Extending the T.I.M.E. concept: what have we learned in the past 10 years? Int Wound J. 2012; 9 (Suppl 2):1-19.
2) Pudner R. 2015, ‘The Edge of T.I.M.E.: exploring epithelial advancement in chronic wounds’, Dermatological Nursing, 14, 2, pp. 32-36.